{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T12:20:02Z","timestamp":1769602802669,"version":"3.49.0"},"reference-count":29,"publisher":"American Academy of Pediatrics (AAP)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2006,8,1]]},"abstract":"<jats:p>CONTEXT AND OBJECTIVE. Primary generalized tonic-clonic seizures are relatively more common among children than among adults. Primary generalized tonic-clonic seizures are associated with increased risk of injury and death. Therefore, effective control of primary generalized tonic-clonic seizures is necessary to reduce epilepsy-related morbidity and mortality. Lamotrigine has demonstrated efficacy from published randomized clinical trials for childhood partial seizures, absence seizures, and for the generalized seizures associated with Lennox-Gastaut syndrome. A randomized, blinded, placebo-controlled study was conducted to assess the efficacy and tolerability of adjunctive therapy with lamotrigine in the treatment of primary generalized tonic-clonic seizures among patients \u22652 years of age; we report the data from children and adolescents 2 to 20 years of age from this randomized clinical trial. This is the first published analysis of data from a randomized, double-blind, controlled clinical trial of primary generalized tonic-clonic seizures focusing on children and adolescents.<\/jats:p><jats:p>PATIENTS AND METHODS. We randomly assigned (1:1) 117 patients, aged 2 to 55 years, with primary generalized tonic-clonic seizures inadequately controlled on 1 to 2 current antiepileptic drugs and with evidence of primary generalized tonic-clonic seizures on electroencephalogram and no historical or electroencephalogram evidence of partial seizures to either lamotrigine or placebo in a double-blind parallel group clinical trial from 2001 through 2004. We analyzed the subgroup of children and adolescents, aged 2 to 20 years (n = 45), from this randomized clinical trial. Patients having \u22653 primary generalized tonic-clonic seizures over an 8-week baseline were randomly assigned (1:1) to receive either lamotrigine or placebo. The treatment period consisted of an escalation phase (12 weeks for patients 2\u201312 years; 7 weeks for patients &amp;gt;12 years) and a maintenance phase (12 weeks). The study had 4 phases: screening phase, baseline phase, escalation phase, and maintenance phase. During the screening phase, baseline medical examinations and seizure type and seizure frequency assessments were performed. During the 8-week baseline phase, the number and dosages of concomitant antiepileptic drugs were maintained while seizure frequency was assessed. The assessment of primary generalized tonic-clonic seizure frequency was determined during the 8-week baseline phase. Patients eligible for random assignment experienced \u22653 primary generalized tonic-clonic seizures during the baseline phase and \u22651 primary generalized tonic-clonic seizure in the 8 weeks before the baseline phase. Lamotrigine was introduced and titrated using a schedule based on the patients' age and concurrent antiepileptic drug regimen. During the escalation phase, the number and doses of concomitant antiepileptic drugs were not changed. The escalation phase was followed by a 12-week maintenance phase during which time the lamotrigine dose was maintained at a specific dose defined by the patients' age and concomitant antiepileptic drugs, whereas the doses of concurrent antiepileptic drugs were maintained at a constant dose. Concurrent antiepileptic drugs could not be discontinued or added during the maintenance phase. The primary efficacy end point measure was the median reduction in the frequency of primary generalized tonic-clonic seizures from baseline; seizure counts were recorded prospectively in standardized daily seizure diaries. Other efficacy end point data for analysis were as follows: the median seizure counts, the median percentage change from the baseline phase in average monthly seizure frequency for other generalized seizure types, and the percentage of patients with a reduction of \u226525%, \u226550%, \u226575%, or 100% in frequencies of primary generalized tonic-clonic seizures and all generalized seizures during the escalation phase and\/or maintenance phase relative to the baseline phase. Accurate counts of absence seizure frequency require electroencephalogram-video monitoring; absence seizure frequency was not an outcome measure for this analysis.<\/jats:p><jats:p>RESULTS. Forty-five (21 lamotrigine and 24 placebo) patients 2 to 19 years of age were randomly assigned and received study drug. Eight patients (3 lamotrigine and 5 placebo) had a combination of clinical (myoclonus and\/or absence seizures) and electroencephalogram findings that were consistent with juvenile myoclonic epilepsy. Among the 45 children randomly assigned, 74% had generalized spike, polyspike, and\/or generalized spike and wave discharges on routine electroencephalogram recordings; the remaining 26% of children had no electroencephalogram findings suggestive of partial epilepsy and a clear history consistent with primary generalized tonic-clonic seizures. Electroencephalogram findings were not significantly different between the lamotrigine and the placebo treatment groups. The median percentage decrease from baseline in primary generalized tonic-clonic seizures during the entire treatment period was 77% in the lamotrigine group and 40% in the placebo group (P = .044). The median primary generalized tonic-clonic seizure counts per month were 0.7 in the lamotrigine group and 3.6 in the placebo group during escalation (P = .008), 0.3 in the lamotrigine group and 2.0 in the placebo group during maintenance (P = .005), and 0.4 in the lamotrigine group and 2.5 in the placebo group during the entire treatment period (P = .007). Trends were noted during escalation and maintenance with a median percentage decrease in primary generalized tonic-clonic seizures during escalation of 72% in the lamotrigine group and 30% in the placebo group (P = .059), and 83% in the lamotrigine group and 42% in the placebo group during maintenance (P = .058). During the maintenance phase, 48% of lamotrigine patients were seizure free compared with 17% treated with placebo (P = .051). One patient from each treatment group discontinued from the study because of an adverse event; 1 patient who received lamotrigine experienced \u201cdisorientation\u201d; and 1 patient who received placebo had a convulsion with apnea. No rashes occurred among patients taking lamotrigine or placebo. No patient experienced worsening of the intensity or frequency of myoclonus.<\/jats:p><jats:p>CONCLUSIONS. Adjunctive lamotrigine therapy seems effective in controlling primary generalized tonic-clonic seizures among patients 2 to 20 years of age.<\/jats:p>","DOI":"10.1542\/peds.2006-0148","type":"journal-article","created":{"date-parts":[[2006,7,18]],"date-time":"2006-07-18T04:35:03Z","timestamp":1153197303000},"page":"e371-e378","source":"Crossref","is-referenced-by-count":38,"title":["Lamotrigine Adjunctive Therapy Among Children and Adolescents With Primary Generalized Tonic-Clonic Seizures"],"prefix":"10.1542","volume":"118","author":[{"given":"Edwin","family":"Trevathan","sequence":"first","affiliation":[{"name":"Pediatric Epilepsy Center, Division of Pediatric and Developmental Neurology, Departments of Neurology and Pediatrics, Washington University in St Louis School of Medicine, St Louis, Missouri"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan P.","family":"Kerls","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline, Research Triangle Park, North Carolina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne E.","family":"Hammer","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline, Research Triangle Park, North Carolina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alain","family":"Vuong","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline, Research Triangle Park, North Carolina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John A.","family":"Messenheimer","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline, Research Triangle Park, North Carolina"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"417","published-online":{"date-parts":[[2006,8,1]]},"reference":[{"key":"2021120822374081100_R1","doi-asserted-by":"crossref","unstructured":"Murphy CC, Trevathan E, Yeargin-Allsopp M. Prevalence of epilepsy and epileptic seizures in 10-year-old children: results from the Metropolitan Atlanta Developmental Disabilities Study. Epilepsia.\u20081995;36:866\u2013872","DOI":"10.1111\/j.1528-1157.1995.tb01629.x"},{"key":"2021120822374081100_R2","doi-asserted-by":"crossref","unstructured":"Zarrelli MM, Beghi E, Rocca WA, Hauser WA. Incidence of epileptic syndromes in Rochester, Minnesota: 1980\u20131984. Epilepsia.\u20081999;40:1708\u20131714","DOI":"10.1111\/j.1528-1157.1999.tb01587.x"},{"key":"2021120822374081100_R3","doi-asserted-by":"crossref","unstructured":"Buck D, Baker GA, Jacoby A, Smith DF, Chadwick DW. Patients' experiences of injury as a result of epilepsy. Epilepsia.\u20081997;38:439\u2013444","DOI":"10.1111\/j.1528-1157.1997.tb01733.x"},{"key":"2021120822374081100_R4","doi-asserted-by":"crossref","unstructured":"Forsgren L, Hauser WA, Olafsson E, Sander JW, Sillanpa\u0308a\u0308 M, Tomson T. Mortality of epilepsy in developed countries: a review. Epilepsia.\u20082005;46(suppl 11):18\u201327","DOI":"10.1111\/j.1528-1167.2005.00403.x"},{"key":"2021120822374081100_R5","doi-asserted-by":"crossref","unstructured":"Duchowny M, Pellock JM, Graf WD, et al. A placebo-controlled trial of lamotrigine add-on therapy for partial seizures in children. Neurology.\u20081999;53:1724\u20131731","DOI":"10.1212\/WNL.53.8.1724"},{"key":"2021120822374081100_R6","doi-asserted-by":"crossref","unstructured":"Coppola G, Auricchio G, Federico R, Carotenuto M, Pascotto A. Lamotrigine versus valproic acid as first-line monotherapy in newly diagnosed typical absence seizures: an open-label, randomized, parallel-group study. Epilepsia.\u20082004;45:1049\u20131053","DOI":"10.1111\/j.0013-9580.2004.40903.x"},{"key":"2021120822374081100_R7","doi-asserted-by":"crossref","unstructured":"Frank LM, Enlow T, Holmes GL, et al. Lamictal (lamotrigine) monotherapy for typical absence seizures in children. Epilepsia.\u20081999;40:973\u2013979","DOI":"10.1111\/j.1528-1157.1999.tb00805.x"},{"key":"2021120822374081100_R8","doi-asserted-by":"crossref","unstructured":"Motte J, Trevathan E, Arvidsson JF, Barrera MN, Mullens EL, Manasco P. Lamotrigine for generalized seizures associated with the Lennox-Gastaut syndrome. Lamictal Lennox-Gastaut Study Group [published correction appears in N Engl J Med. 1998;1339:1851\u20131802]. N Engl J Med.\u20081997;337:1807\u20131812","DOI":"10.1056\/NEJM199712183372504"},{"key":"2021120822374081100_R9","doi-asserted-by":"crossref","unstructured":"Mikati MA, Holmes GL. Lamotrigine in absence and primary generalized epilepsies. J Child Neurol.\u20081997;12(suppl 1):S29\u2013S37","DOI":"10.1177\/0883073897012001081"},{"key":"2021120822374081100_R10","doi-asserted-by":"crossref","unstructured":"Gericke CA, Picard F, de Saint-Martin A, Strumia S, Marescaux C, Hirsch E. Efficacy of lamotrigine in idiopathic generalized epilepsy syndromes: a video-EEG-controlled, open study. Epileptic Disord.\u20081999;1:159\u2013165","DOI":"10.1684\/j.1950-6945.1999.tb00315.x"},{"key":"2021120822374081100_R11","doi-asserted-by":"crossref","unstructured":"Brodie MJ, Richens A, Yuen AW. Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. UK Lamotrigine\/Carbamazepine Monotherapy Trial Group [published correction appears in Lancet. 1995;1345:1662]. Lancet.\u20081995;345:476\u2013479","DOI":"10.1016\/S0140-6736(95)90581-2"},{"key":"2021120822374081100_R12","doi-asserted-by":"crossref","unstructured":"Steiner TJ, Dellaportas CI, Findley LJ, et al. Lamotrigine monotherapy in newly diagnosed untreated epilepsy: a double-blind comparison with phenytoin. Epilepsia.\u20081999;40:601\u2013607","DOI":"10.1111\/j.1528-1157.1999.tb05562.x"},{"key":"2021120822374081100_R13","doi-asserted-by":"crossref","unstructured":"Brodie MJ, Chadwick DW, Anhut H, et al. Gabapentin versus lamotrigine monotherapy: a double-blind comparison in newly diagnosed epilepsy. Epilepsia.\u20082002;43:993\u20131000","DOI":"10.1046\/j.1528-1157.2002.45401.x"},{"key":"2021120822374081100_R14","doi-asserted-by":"crossref","unstructured":"Biton V, Sackellares JC, Vuong A, Hammer AE, Barrett PS, Messenheimer JA. Double-blind, placebo-controlled study of lamotrigine in primary generalized tonic-clonic seizures. Neurology.\u20082005;65:1737\u20131743","DOI":"10.1212\/01.wnl.0000187118.19221.e4"},{"key":"2021120822374081100_R15","doi-asserted-by":"crossref","unstructured":"Lerman-Sagie T, Lerman P. Dramatic effect of lamotrigine in young adults suffering from intractable absences and generalized tonic-clonic seizures since childhood. J Epilepsy.\u20081998;11:148\u2013151","DOI":"10.1016\/S0896-6974(97)00133-3"},{"key":"2021120822374081100_R16","doi-asserted-by":"crossref","unstructured":"Kochen S, Giagante B, Oddo S. Spike-and-wave complexes and seizure exacerbation caused by carbamazepine. Eur J Neurol.\u20082002;9:41\u201347","DOI":"10.1046\/j.1468-1331.2002.00317.x"},{"key":"2021120822374081100_R17","doi-asserted-by":"crossref","unstructured":"Snead OC 3rd, Hosey LC. Exacerbation of seizures in children by carbamazepine. N Engl J Med.\u20081985;313:916\u2013921","DOI":"10.1056\/NEJM198510103131503"},{"key":"2021120822374081100_R18","doi-asserted-by":"crossref","unstructured":"Sazgar M, Bourgeois BF. Aggravation of epilepsy by antiepileptic drugs. Pediatr Neurol.\u20082005;33:227\u2013234","DOI":"10.1016\/j.pediatrneurol.2005.03.001"},{"key":"2021120822374081100_R19","doi-asserted-by":"crossref","unstructured":"The Group for the evaluation of cinromide in the Lennox-Gastaut syndrome. Double-blind, placebo-controlled evaluation of cinromide in patients with the Lennox-Gastaut syndrome. Epilepsia.\u20081989;30:422\u2013429","DOI":"10.1111\/j.1528-1157.1989.tb05321.x"},{"key":"2021120822374081100_R20","doi-asserted-by":"crossref","unstructured":"Biton V, Montouris GD, Ritter F, et. al. A randomized, placebo-controlled study of topiramate in primary generalized tonic-clonic seizures. Neurology.\u20081999;52:1330\u20131337","DOI":"10.1212\/WNL.52.7.1330"},{"key":"2021120822374081100_R21","doi-asserted-by":"crossref","unstructured":"Chadwick D, Leiderman DB, Sauermann W, et. al. Gabapentin in generalized seizures. Epilepsy Res.\u20081996:191\u2013197","DOI":"10.1016\/S0920-1211(96)00020-4"},{"key":"2021120822374081100_R22","doi-asserted-by":"crossref","unstructured":"Sillanpaa M, Jalava M, Kaleva O, Shinnar S. Long-term prognosis of seizures with onset in childhood. N Engl J Med.\u20081998;338:1715\u20131722","DOI":"10.1056\/NEJM199806113382402"},{"key":"2021120822374081100_R23","doi-asserted-by":"crossref","unstructured":"Pellock JM, Wilder BJ, Deaton R, Sommerville KW. Acute pancreatitis coincident with valproate use: a critical review. Epilepsia.\u20082002;43:1421\u20131424","DOI":"10.1046\/j.1528-1157.2002.18502.x"},{"key":"2021120822374081100_R24","doi-asserted-by":"crossref","unstructured":"Biton V, Mirza W, Montouris GD, Vuong A, Hammer AE, Barrett PS. Weight change associated with valproate and lamotrigine monotherapy in patients with epilepsy. Neurology.\u20082001;2001:172\u2013177","DOI":"10.1212\/WNL.56.2.172"},{"key":"2021120822374081100_R25","doi-asserted-by":"crossref","unstructured":"Nelson-DeGrave VL, Wickenheisser JK, Cockrell JE, et al. Valproate potentiates androgen biosynthesis in human ovarian theca cells. Endocrinology.\u20082004;145:799\u2013808","DOI":"10.1210\/en.2003-0940"},{"key":"2021120822374081100_R26","doi-asserted-by":"crossref","unstructured":"Gross-Tsur V, Shalev RS. Reversible language regression as an adverse effect of topiramate treatment in children. Neurology.\u20082004;62:299\u2013300","DOI":"10.1212\/01.WNL.0000103285.85821.B3"},{"key":"2021120822374081100_R27","doi-asserted-by":"crossref","unstructured":"Messenheimer JA. Rash in adult and pediatric patients treated with lamotrigine. Can J Neurol Sci.\u20081998;25:S14\u2013S18","DOI":"10.1017\/S0317167100034910"},{"key":"2021120822374081100_R28","doi-asserted-by":"crossref","unstructured":"Guberman AH, Besag FM, Brodie MJ, et al. Lamotrigine-associated rash: risk\/benefit considerations in adults and children. Epilepsia.\u20081999;40:985\u2013991","DOI":"10.1111\/j.1528-1157.1999.tb00807.x"},{"key":"2021120822374081100_R29","doi-asserted-by":"crossref","unstructured":"Crespel A, Genton P, Berramdane M, et al. Lamotrigine associated with exacerbation or de novo myoclonus in idiopathic generalized epilepsies. Neurology.\u20082005;65:762\u2013764","DOI":"10.1212\/01.wnl.0000174517.21383.36"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/118\/2\/e371\/1073626\/zpe0080600e371.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/118\/2\/e371\/1073626\/zpe0080600e371.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T23:15:51Z","timestamp":1736464551000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/118\/2\/e371\/68932\/Lamotrigine-Adjunctive-Therapy-Among-Children-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,8,1]]},"references-count":29,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2006,8,1]]},"published-print":{"date-parts":[[2006,8,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2006-0148","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,8,1]]}}}